What is the efficacy of ambrisentan for the treatment of pulmonary arterial hypertension (PAH)?

Updated: Aug 25, 2020
  • Author: Kristin E Schwab, MD; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print

Ambrisentan is a selective type A endothelin-1 antagonist [55] indicated for the treatment of PAH (1) to improve exercise ability and delay clinical worsening and (2) in combination with tadalafil to improve exercise ability, as well as reduce the risks of disease progression and hospitalization for worsening PAH. It inhibits vessel constriction and elevation of blood pressure by competitively binding to EtA and EtB receptors in endothelium and vascular smooth muscle. This leads to a significant increase in cardiac index associated with significant reductions in pulmonary arterial pressure, pulmonary vascular resistance, and mean right atrial pressure. While the incidence of LFT abnormalities is less with ambrisentan compared with bosentan, ambrisentan is available only through the Letairis Education and Access Program (LEAP). Prescribers and pharmacies must register with LEAP in order to prescribe and dispense. For more information, see http://www.letairis.com or call (866) 664-LEAP (5327).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!